Greenland Mines (NASDAQ: GRML) announced today that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
This news matters because it strengthens Greenland Mines' intellectual property portfolio for Klotho-based therapeutics, a promising approach to address devastating neurological conditions that currently lack effective treatments. The Canadian patent complements previously issued patents in the United States, China and Europe, creating a broad geographic protection for the company's proprietary technology. For patients and healthcare systems, the advancement of Klotho gene therapy could eventually provide new options for diseases that affect millions worldwide, potentially slowing or reversing cognitive decline.
Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The progression of these candidates toward clinical trials underscores the company's commitment to translating its patented technology into tangible therapies. For investors, the expanding IP portfolio and manufacturing milestones signal a maturing pipeline that could lead to significant value creation if clinical trials succeed.
The company operates two divisions: mining, focused on the Skaergaard Project in Greenland and the Sarfartoq rare earths project, and biotech, including Klotho’s KLTO‑202 primary indication for ALS. This dual focus allows Greenland Mines to leverage synergies between its resource and life sciences operations while advancing its broader North Atlantic Critical Metals Corridor vision. The patent news highlights the biotech division's progress and its potential to impact the neurodegenerative disease landscape.
To view the full press release, visit: https://ibn.fm/x2pHA. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings. Greenland Mines undertakes no duty to update this information unless required by law.
